Placebo + RLX030
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-eclampsia
Conditions
Pre-eclampsia
Trial Timeline
May 1, 2013 → Aug 1, 2014
NCT ID
NCT01566630About Placebo + RLX030
Placebo + RLX030 is a phase 2 stage product being developed by Novartis for Pre-eclampsia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01566630. Target conditions include Pre-eclampsia.
What happened to similar drugs?
0 of 1 similar drugs in Pre-eclampsia were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01566630 | Phase 2 | Terminated |
Competing Products
3 competing products in Pre-eclampsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| recombinant human relaxin | Novartis | Phase 1 | 33 |
| Sildenafil citrate | Pfizer | Phase 2 | 27 |
| Furosemide | Pacific Biosciences | Phase 3 | 30 |